Hormonal
Next-generation multi-receptor agonists (e.g., Tirzepatide, a dual GLP-1/GIP agonist) offer superior weight loss and metabolic efficacy compared to single GLP-1RAs.
If single GLP-1 medications (like Ozempic or Wegovy) aren't providing enough weight loss or metabolic improvement, ask your doctor about dual-agonists like Tirzepatide. These newer drugs target two hormones (GLP-1 and GIP) and have shown even greater weight loss in clinical trials. They are approved for both diabetes and obesity management.
An example is tirzepatide, a dual GLP-1/GIP receptor agonist, which has been approved for both T2D and obesity management, demonstrating up to 22.5% weight loss in phase 3 trials.
Why this rating
Supported by Phase 3 trials, but long-term cardiorenal outcomes for multi-agonists are less established than for single GLP-1RAs in this review.
Source
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Ellen M. Apperloo et al. · Nephrology Dialysis Transplantation · 2025
DOI 10.1093/ndt/gfaf110
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →